(Q44528478)

3 December 2017

1 reference

title

Nelfinavir. A review of its therapeutic efficacy in HIV infection (English)

1 reference

3 December 2017

1 reference

B Jarvis

1

1 reference

3 December 2017

D Faulds

series ordinal

2

1 reference

3 December 2017

publication date

1 July 1998

1 reference

3 December 2017

1 reference

3 December 2017

volume

56

1 reference

3 December 2017

issue

1

1 reference

3 December 2017

page(s)

147-167

1 reference

Guidelines for the use of antiretroviral agents in pediatric HIV infection. Center for Disease Control and Prevention

3 December 2017

cites work

1 reference

12 December 2020

Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors

1 reference

12 December 2020

Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use.

1 reference

12 December 2020

Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice

1 reference

12 December 2020

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

12 December 2020

British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Co-ordinating Committee

1 reference

12 December 2020

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

1 reference

12 December 2020

Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease

1 reference

12 December 2020

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

12 December 2020

Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions

1 reference

12 December 2020

HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time

1 reference

12 December 2020

Protease inhibitors: a therapeutic breakthrough for the treatment of patients with human immunodeficiency virus

1 reference

12 December 2020

Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex

1 reference

12 December 2020

HIV-1 protease inhibitors. A review for clinicians

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel

1 reference

12 December 2020

Guidelines for antiretroviral therapy for HIV infection. Canadian HIV Trials Network Antiretroviral Working Group.

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients

1 reference

12 December 2020

HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy

1 reference

12 December 2020

1 reference

12 December 2020

HIV-1 protease inhibitors

1 reference

12 December 2020

The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection

1 reference

12 December 2020

Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro

1 reference

12 December 2020

Anti-HIV activity of adefovir (PMEA) and PMPA in combination with antiretroviral compounds: in vitro analyses

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

Severe diabetes associated with protease inhibitor therapy

1 reference

12 December 2020

On the issue of cross-resistance between protease inhibitors.

1 reference

12 December 2020

The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir.

1 reference

12 December 2020

Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease

1 reference

12 December 2020

Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy

1 reference

12 December 2020

Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations

1 reference

12 December 2020

The role of combinations of HIV protease inhibitors in the management of persons with HIV infection.

1 reference

12 December 2020

Decay characteristics of HIV-1-infected compartments during combination therapy

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

10.2165/00003495-199856010-00013

Identifiers

DOI

1 reference

Dimensions Publication ID

3 December 2017

1022695461

0 references

Fatcat ID

release_asuuetbvjjb2vkfrsr2dcg5hmm

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/asuuetbvjjb2vkfrsr2dcg5hmm

24 November 2022

mapped directly with Wikidata item

1 reference